Abstract: Provided herein are long lasting hair styling compositions and markers for selecting the same.

Abstract: The present invention relates to a method of obtaining a novel gelling agent. Said method comprises adding ethylcellulose, to a mixture of propyleneglycol laurate and propyleneglycol isostearate at a temperature of between 90° C. and 110° C. The method according to the invention provides a simpler, less energy consuming, cheaper and easier way of obtaining a substantially gelling agent which can be used for manufacturing an oleogel and/or a bigel, for cosmetic and/or pharmaceutical use.

Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and pyrethrum esters and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and pyrethrum esters.

Abstract: The present invention provides resin beads that can provide various types of products such as cosmetics which are unlikely to generate an odor and have superior tactile impression and spreadability on the skin and that can be substituted for resin particles composed of a synthetic material derived from petroleum, and the present invention also provides various types of products such as cosmetics using the resin beads. The resin beads are formed with a resin containing a cellulose derivative as a main component. In the resin beads, the cellulose derivative is at least one selected from the group consisting of cellulose acetate, cellulose acetate propionate, ethyl cellulose, and hydroxypropyl methyl cellulose, the volume average particle diameter is 50 ?m or smaller, the degree of sphericity is 0.7 to 1.0, the degree of surface smoothness is 80 to 100%, the acetyl group content ratio is 15% by mass or less, and the propionyl group content ratio is 10% by mass or more.

Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.

Abstract: Personal cleansing compositions having an anionic surfactant, cationic deposition polymer, a level of inorganic salt of from about 0 to about 1 wt %, and an aqueous carrier. The composition is substantially free of sulfate containing surfactants. The composition can further comprise amphoteric surfactants. The composition remains phase stable, and minimizes coacervate formulation until after dilution with water.

Abstract: An optically clear, solid water-soluble formulation of odorants and flavorings comprising at least one synthetically prepared odorant and flavoring, in which the odorants and flavorings are embedded homogeneously in a polymer matrix based on polyvinyllactams.

Abstract: The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.

Abstract: The invention relates to radiopaque liquid embolic composition comprising tetra iodo compound, 4,4-bis (4-hydroxy-3,5 diiodo phenyl) valeric acid (IBHV) of Formula I, covalently linked to ethylene vinyl alcohol copolymer (EVOH) and dissolved in a water miscible organic liquid.

Abstract: A hair care oil composition including Eclipta alba. The compositions are useful for treating the hair and scalp.

Abstract: Disclosed are cationic polymers comprising monomers such as those described in Formula (I). Such polymers can be useful for the preparation of therapeutic compositions [e.g., compositions comprising nucleic acids such as m RNA). Additionally, therapeutic compositions comprising these cationic, biodegradable polymers can have improved properties and reduced toxicity.

Abstract: This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine.

Abstract: A water-in-oil emulsion composition that is significantly excellent in emulsification stability, and also excellent in non-stickiness is provided. The water-in-oil emulsion composition includes (a) a polyoxyalkylene/alkyl co-modified silicone; (b) a core-corona particle; (c) an oil-phase component; and (d) an aqueous-phase component.

Abstract: The instant disclosure is directed to compositions comprising an encapsulated spheroid, and methods of making and using the same. A composition may comprise a spheroid comprising a plurality of cells and aminoglycoside antibiotic-derived hydrogel beads, wherein the spheroid is encapsulated by the aminoglycoside antibiotic-derived hydrogel beads to form an encapsulated spheroid. A method may comprise administering the composition to a subject in need thereof. Another method may comprise administering a compound to the encapsulated spheroid. A method of creating an encapsulated spheroid may comprise coating a surface with an aminoglycoside antibiotic-derived hydrogel, culturing a plurality of cells on the surface, thereby creating a spheroid, and encapsulating the spheroid with a plurality of aminoglycoside antibiotic-derived hydrogel beads.

Abstract: The present invention provides a method of inhibiting tolerance to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

Abstract: A clear personal cleansing composition having an anionic surfactant, a cationic deposition polymer, an aqueous carrier and a level of inorganic salt of from about 0 to about 1 wt %. The composition is substantially free of sulfates and has a % T of greater than about 80%. The composition can further comprise amphoteric surfactants. The composition remains phase stable and minimizes coacervate formulation until after dilution with water.

Abstract: A universal mineral based sunscreen that is good for all skin colors and prevents any ashy visual appearance on all colors of skin.

Abstract: A sunscreen comprises red iron oxide and a mineral sunscreen blend, that is universal with all skin colors and prevents ashy skin.

Abstract: Disclosed is agents and methods that target metabolism malfunctions, inborne as well as acquired, as well as methods for preparation of the agents. In particular, the invention relates to methods for preparing molecular imprinted polymers with high binding capacity for phenylalanine or tyrosine, MIPs that bind phenylalanine or tyrosine, and methods for treating phenylketonuria, alkaptonuria, and hypertyrosinemia.

Abstract: An antimicrobial article that includes: an antimicrobial composite region that includes a matrix comprising a polymeric material, and a first plurality of particles within the matrix. The particles include a phase-separable glass with a copper-containing antimicrobial agent. The antimicrobial composite region can be a film containing the first plurality of particles that is subsequently laminated to a bulk element. The first plurality of particles can also be pressed into the film or a bulk element to define an antimicrobial composite region. An exposed surface portion of the antimicrobial composite region can exhibit at least a log 2 reduction in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, and Pseudomonas aeruginosa bacteria under a Modified EPA Copper Test Protocol.